* Q1 loss/shr $0.19 vs est loss/shr $0.20
* Net revenue up 20 pct
May 5 (BestGrowthStock) – Dialysis products maker NxStage Medical
Inc (NXTM.O: ) posted a narrower-than-expected quarterly loss,
helped by strong performance across its home and critical care
segments.
For the first quarter, the company posted a net loss of
$9.0 million, or 19 cents a share, compared with a net loss of
$12.2 million, or 26 cents a share, in the year-ago period.
Analysts were expecting a loss of 20 cents a share,
according to Thomson Reuters I/B/E/S.
Total revenue rose 20 percent to $40.4 million, beating
analysts’ estimates of $38.81 million. Its home market grew 33
percent while its critical care segment grew 36 percent.
For the alerts, please click on [ID:nASA00BF1]
Shares of NxStage closed at $12.89 Tuesday on Nasdaq.
Stock Investing
(Reporting by Jennifer Robin Raj in Bangalore; Editing by
Ratul Ray Chaudhuri)
UPDATE 1-NxStage posts narrower-than-expected quarterly loss
